 TORONTO, ON ACCESSWIRE July 13, 2021 Edesa Biotech, Inc. NASDAQ:EDSA, a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company has expanded patient enrollment to Canada for the final part of a Phase 2b study evaluating its EB01 drug candidate as a monotherapy for chronic Allergic Contact Dermatitis Eczema, or ACD. The first part of the ACD study was conducted in the United States, where enrollment is ongoing. 